» Articles » PMID: 17664319

High-throughput Screens for Small-molecule Inhibitors of Pseudomonas Aeruginosa Biofilm Development

Overview
Specialty Pharmacology
Date 2007 Aug 1
PMID 17664319
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Pseudomonas aeruginosa is both a model biofilm-forming organism and an opportunistic pathogen responsible for chronic lung infections in cystic fibrosis (CF) patients and infections in burn patients, among other maladies. Here we describe the development of an efficient high-throughput screen to identify small-molecule modulators of biofilm formation. This screen has been run with 66,095 compounds to identify those that prevent biofilm formation without affecting planktonic bacterial growth. The screen is a luminescence-based attachment assay that has been validated with several strains of P. aeruginosa and compared to a well-established but low-throughput crystal violet staining biofilm assay. P. aeruginosa strain PAO1 was selected for use in the screen both because it forms robust biofilms and because genetic information and tools are available for the organism. The attachment-inhibited mutant, strain PAO1 DeltafliC, was used as a screening-positive control. We have also developed and validated a complementary biofilm detachment assay that can be used as an alternative primary screen or secondary screen for the attachment screening-positive compounds. We have determined the potencies of 61 compounds against biofilm attachment and have identified 30 compounds that fall into different structural classes as biofilm attachment inhibitors with 50% effective concentrations of less than 20 microM. These small-molecule inhibitors could lead to the identification of their relevant biofilm targets or potential therapeutics for P. aeruginosa infections.

Citing Articles

Biofilm Production in Intensive Care Units: Challenges and Implications.

Taner F, Baddal B, Theodoridis L, Petrovski S Pathogens. 2024; 13(11).

PMID: 39599508 PMC: 11597785. DOI: 10.3390/pathogens13110954.


The Association between Biofilm Formation and Antimicrobial Resistance with Possible Ingenious Bio-Remedial Approaches.

Dutt Y, Dhiman R, Singh T, Vibhuti A, Gupta A, Pandey R Antibiotics (Basel). 2022; 11(7).

PMID: 35884186 PMC: 9312340. DOI: 10.3390/antibiotics11070930.


Using to Model Therapeutic Interventions of Neurodegenerative Diseases Targeting Microbe-Host Interactions.

Wang C, Zheng C Front Pharmacol. 2022; 13:875349.

PMID: 35571084 PMC: 9096141. DOI: 10.3389/fphar.2022.875349.


Attenuation of Infection in by YtnP, a -acyl Homoserine Lactonase from T-1.

Peng M, Tong W, Zhao Z, Xiao L, Wang Z, Liu X Antibiotics (Basel). 2021; 10(6).

PMID: 34073161 PMC: 8228444. DOI: 10.3390/antibiotics10060631.


High-Throughput Approaches for the Identification of Antivirulents.

Kang D, Zhang L, Kirienko N mBio. 2021; 12(3).

PMID: 33947765 PMC: 8262948. DOI: 10.1128/mBio.02240-20.


References
1.
Fleiszig S, Arora S, Van R, Ramphal R . FlhA, a component of the flagellum assembly apparatus of Pseudomonas aeruginosa, plays a role in internalization by corneal epithelial cells. Infect Immun. 2001; 69(8):4931-7. PMC: 98584. DOI: 10.1128/IAI.69.8.4931-4937.2001. View

2.
Manefield M, de Nys R, Naresh K, Roger R, Givskov M, Peter S . Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein. Microbiology (Reading). 1999; 145 ( Pt 2):283-291. DOI: 10.1099/13500872-145-2-283. View

3.
Friedman L, Kolter R . Two genetic loci produce distinct carbohydrate-rich structural components of the Pseudomonas aeruginosa biofilm matrix. J Bacteriol. 2004; 186(14):4457-65. PMC: 438632. DOI: 10.1128/JB.186.14.4457-4465.2004. View

4.
Parsek M, Singh P . Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol. 2003; 57:677-701. DOI: 10.1146/annurev.micro.57.030502.090720. View

5.
Habash M, Reid G . Microbial biofilms: their development and significance for medical device-related infections. J Clin Pharmacol. 1999; 39(9):887-98. DOI: 10.1177/00912709922008506. View